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One of the persistent challenges in the diagnosis and control 
of bovine tuberculosis (bTB) has been the difficulty in detect-
ing infected animals at all stages of infection. This is attribut-
able in part to the lack of a full understanding of the immune 
response to the pathogen Mycobacterium bovis.1,8,13 and also 
to the lack of an assay that detects all infected animals. Most 
animals develop a cell-mediated immune response (CMI) fol-
lowing infection that is detectable as a delayed type hypersen-
sitivity reaction after intradermal injection of M. bovis 
antigens, usually purified protein derivative (PPD). Recogni-
tion of this phenomenon led to the development of the first 
diagnostic assay for bTB, the tuberculin skin test. The test 
was used successfully in the United States to reduce the inci-
dence of bTB during the past century. It is the main surveil-
lance tool currently used to control recurrent outbreaks 
attributable to wildlife reservoirs in white-tailed deer (Odocoi-
leus virginianus) in some areas of the United States and the 
inadvertent introduction of infected animals from other coun-
tries. Test and cull methodologies have been less successful, 
however, in countries such as Ireland, the United Kingdom, 
and New Zealand where M. bovis is endemic in wildlife res-
ervoirs such as badgers (Meles meles) and possums (Trichor-
surus vulpecula) and where cattle herds are constantly being 
re-exposed. The single intradermal comparative tuberculin 
skin test (SICTT) form of the tuberculin skin test is the stan-
dard assay used in Ireland and the United Kingdom. This 
form of the test involves the use of PPD derived from M. bovis, 
strain AN5, and Mycobacterium avium subsp. avium. The 
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Abstract. Although the single intradermal comparative tuberculin skin test (SICTT) remains the most effective assay for 
detecting cattle infected with Mycobacterium bovis, not all infected animals are detected with the SICTT. This has made it 
difficult to control bovine tuberculosis using a single assay. Use of the gamma interferon assay in conjunction with the SICTT 
has improved the level of detection but some infected animals still go undetected. This could be in part attributable to both 
assays being reliant on a cell-mediated immune response. The present study was undertaken to determine if a multiplex assay 
can improve the level of detection of infected animals when used in combination with the SICTT. The Enferplex TB assay is a 
multi-antigen ELISA designed for the detection of antibody in animals at different stages of infection and disease. Sixty cattle 
that were confirmed by histopathology and/or culture to be infected with M. bovis and that were SICTT negative (43.3%) or 
difficult to evaluate (56.7% inconclusive) were used in the study. Fifty-three (88.3%) of the animals were positive in multiplex 
ELISA. The results show that the level of detection of M. bovis–infected animals can be improved by the combined use of the 
SICTT and the multiplex ELISA.
Key words: Bovine tuberculosis; chemiluminescent; multiplex; Mycobacterium bovis; single intradermal comparative 
tuberculin test.
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SICTT uses bovine and avian tuberculin PPDs in combina-
tion to assess, measure, and compare the response at 72 ± 4 hr 
following intradermal injection so as to determine the infec-
tion status of the animal and herd. The sensitivity of the 
SICTT has been reported to range from 80% to 95% with 
ranges of specificity reported as 96–99%.9,14,18 In spite of the 
effectiveness of the SICTT in reducing the incidence of 
infected animals at the herd level, some animals are not 
detected with the SICTT, leaving herds at risk for bovine-to-
bovine spread of infection.
The inability to detect all infected animals has prompted 
efforts to develop a better diagnostic assay to replace the 
SICTT or ancillary assays that increase the ability to detect 
most infected animals when used in conjunction with the 
SICTT. The introduction of the gamma interferon (IFNγ) 
assay as an ancillary confirmatory assay has increased the 
effectiveness of the SICTT but infected animals may still be 
missed. Efforts to develop a serological assay to use alone or 
in conjunction with the SICTT revealed the complexity of the 
antibody response to M. bovis and the reasons why develop-
ment of an antibody based assay has proven difficult. The anti-
body response to TB-specific antigens is highly variable with 
the titer of antibody activity changing during different stages 
of infection. No single antigen has, thus far, been identified 
that elicits a response in all animals during different stages of 
infection. As reported in a 2009 review,15 many infected ani-
mals are missed with assays based on the use of a single anti-
gen. Attempts to increase the sensitivity of the assay using 
multiple antigens showed this approach has the potential of 
increasing the ability to detect more infected animals.2,6 
However, attempts to use the standard ELISA platform, with a 
mixture of multiple antigens, have not been successful. 
Sensitivity is reduced due to problems with equal binding of 
included antigens. To address this problem, a chemilumines-
cent multiplex assay has been designed to detect antibodies to 
multiple antigens spotted in a single well of a 96-well plate. 
Initial studies in an unblinded assay, using defined infection 
status samples, showed a sensitivity of 93.1% and specificity 
of 98.4% can be achieved using a combination of antigens.16 A 
subsequent blinded studied showed a relative sensitivity 
between 77.1% and 86.5% and specificity between 79.6% and 
100% can be achieved depending on the stringency of criteria 
used for the complex cut off levels.17 A further study4 was con-
ducted using samples taken contemporaneously with the 
injection of tuberculin during the performance of the SICTT in 
herds where the infection risk is high and in herds where the 
infection risk is very low. This study showed by latent class 
analysis that the sensitivity of multiplex assay (high sensitivity 
interpretation; 95% confidence interval [CI]: 64.8–71.9%) 
was superior to the SICTT [standard], and the specificity of 
the multiplex assay (high specificity interpretation) was supe-
rior to IFNγ (95% CI: 99.6–100.0%).
The objective of the present study was to assess the poten-
tial usefulness of the multiplex assay as an ancillary test with 
the SICTT to increase the ability to identify infected animals 
that were negative or inconclusive for the SICTT. The study 
was conducted with serum samples obtained from 60 animals 
present in 41 skin test reactor herds. The animals considered 
for this study were SICTT negative/inconclusive and were 
being removed from herds with M. bovis infection. The SICTT 
was administered approximately 2–3 weeks prior to blood 
samples being taken at slaughter. Anamnestic response is a 
point of concern with serological assays for bTB. Preliminary 
work on samples collected pre- and post-SICTT from both 
bTB-infected and noninfected animals suggests that there is 
no appreciable anamnestic response detectable to the pres-
ently used antigens (unpublished data). However, in a country 
where the SICTT is carried out annually, the use of an ancillary 
serological, with or without an anamnestic component, could 
assist bTB eradication at the herd level. All 60 animals pre-
sented with gross pathology typical of bTB at necropsy.7 The 
sites of lesions were recorded for 53 out of 60 of the animals 
(lymph nodes: bronchial, 20/53; mediastinal, 6/53; retropha-
ryngeal, 2/53; and submandibular, 25/53). Tissue samples 
from 57/60 animals were confirmed positive by histopathol-
ogy and/or acid-fast staining of bacteria. Culture was used to 
confirm the presence of M. bovis in the remaining 3 animals.7
The multiple antigen immunoassaya was carried out as 
previously described.16 Briefly, multiple antigensb,c were 
spotted in individual spots, in a single well of a 96-well plate 
as described according to the manufacturer’s instructions.d 
Following incubation with serum,e washing,a and addition of 
substrate,d the chemiluminescent signal (relative light units) 
was captured with a digital imaging systemd and analyzed 
with softwarea that tracks each serum for its pattern of anti-
body recognition for M. bovis antigens. High sensitivity 
level analysis was used, since samples were from herds 
known to have bTB. The previously established specificity 
of the test at high sensitivity level analysis is 96.5% (n = 
1,800) with a sensitivity of 93.8% (n = 454; Fifth International 
M. bovis Conference, 25–28 August 2009, Wellington, New 
Zealand). The high sensitivity level analysis is based on sig-
nals being obtained above set thresholds for individual anti-
gens for a minimum of 2 antigens in the panel.
Out of the 60 animals tested on the multiplex assay, 53 
out of 60 (88.3%) were detected as positives using the high 
sensitivity analysis thresholds and the 2 antigen rule. 
Twenty-six of the animals were SICTT negative while 34 
were interpreted as inconclusive (Table 1). Figure 1 shows 
Table 1. Comparative results for the multiplex assay and the 
single intradermal comparative tuberculin skin test (inconclusive) 
bovine and avian reaction of 1–4-mm difference.
Multiplex assay  
 Positive Negative Total
Inconclusive 29 5 34
Negative 24 2 26
Total 53 7 60
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representative data for 10 serologically positive animals, 5 of 
which were SICTT negative and 5 SICTT inconclusive. No 
difference in the patterns of serological antigen recognition 
was observed for either group of samples. An independent 
group t-test was carried outf on the signals obtained for each 
antigen at the 5% level the differences when comparing the 
SICTT-negative and SICTT-inconclusive groups was not 
significant (P-values: 0.089–0.474). Table 2 shows the fre-
quency of response to the 7 antigens used in the multiplex 
platform for the 53 animals that yielded positive serological 
results. The data show seropositive results were similar in 
the SICTT negative and inconclusive animals.
All herds in the Republic of Ireland are subjected to an 
annual test for bTB using the SICTT. Herds in which an ani-
mal responds positively to the SICTT (i.e., identified as a 
“reactor”) are said to be experiencing a bTB breakdown, are 
placed under movement control, and are restricted. Test posi-
tive animals are removed from the herd. The SICTT is then 
repeated, normally every 60 days on the positive herd to both 
allow for the post-infection cell-mediated response delay of 
18–51 days11 and to avoid the effects of desensitization.10 
Contiguous herds are also tested to determine if infection is 
restricted to a single herd. Inclusion of the IFNγ test has 
improved the sensitivity of testing but has not reduced the 
required time interval between repeat testing. An outbreak of 
bTB can have a serious effect on farm business and move-
ment restriction, sometimes for extended periods, are par-
ticularly problematic. It is the longer lasting effects of 
continued movement restrictions which typically result in 
significant consequential impact on the economic perfor-
mance and growth of the farm business together with stress 
affecting farmer and those dependent on the cattle enterprise. 
Other invetigators3 also found a correlation between the 
length of the breakdown and total cost of a bTB breakdown. 
The time constraint between SICTTs emphasizes the 
continuing need to explore ways to improve the methods of 
monitoring to decrease the time required to clear infection so 
as to certify a herd clear of bTB. The SICTT also requires 
collection of animals on 2 occasions 72 ± 4 hr apart. Each 
collection of the animals also has resource costs both in 
terms of manpower and time and additional on-farm conse-
quential losses due to reduced milk production in dairy stock 
and loss of body condition in beef cattle on test day.3 It 
should be noted, however, that the use of more sensitive tests 
generally involves a concurrent lower specificity and conse-
quently an increased potential for the identification of addi-
tional false-positive responders. Thus, the choice and use of 
ancillary tests in a diseased herd must be balanced against 
the cost of continued restriction, repeated SICTTs with asso-
ciated costs and ultimately the risk of full herd depopulation 
should the disease not be cleared from the herd.
Extending the test interval between SICTTs might also be 
beneficial for clearance of herds in other respects since there 
are reports in the literature suggesting that excessive testing 
of cattle may reduce their immune response and thus reduce 
the sensitivity of the tests used.5 An antibody-based assay 
offers the possibility of alternative approaches to clearing a 
herd of bTB so as to overcome both the inter-test interval 
time constraint of the SICTT and the additional on-farm 
costs associated with testing over 2 days. It also offers a way 
to overcome the limitations of IFNγ assay (i.e., the need to 
complete the assay within 8 hr of collecting the blood for 
analysis to maximize the extraction of potentially infected 
animals).12 Sera can be collected at any time for immediate 
analysis and stored indefinitely for serial retrospective stud-
ies. Advances in assay design such as the ability to simulta-
neously screen for the presence of antibody to multiple 
antigens are opening new possibilities. Such advances now 
permit design of an assay that includes antigens that elicit 
antibody activity at early and late time points following 
Figure 1. Chart of signal intensities (RLU) for a set of 10 representative multiplex assay positive samples for 7 antigens from the 
multiplex platform. Samples 1–5 are single intradermal comparative tuberculin skin test (SICTT) negative, and samples 6–10 are SICTT 
inconclusive.
*MPB70 is a peptide preparation.
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infection. As shown in the present study, the antigens used in 
the current format of the multiplex assay have the potential 
to increase the sensitivity of the SICTT and other methods 
currently in use for disease surveillance. Herds can be 
screened for the presence of antibody frequently over a 
shorter time frame, allowing the identification of animals 
that might prove positive for SICTT and the Enferplex TB 
assay as well as animals that would be missed if only the 
SICTT were used for monitoring. Use of a multiplex assay 
could accelerate detection and removal of infected animals 
and shorten the time needed to clear a herd from quarantine.
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